• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Assessment of patient-reported outcomes at 24 weeks of treatment with tralokinumab for atopic dermatitis: a multicentric real-life experience.

作者信息

Ferrucci Silvia, Barei Francesca, Tavecchio Simona, Marzano Angelo V, Zussino Martina, Naldi Luigi, Pezzolo Elena

机构信息

Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.

Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy.

出版信息

J Dermatolog Treat. 2023 Dec;34(1):2285243. doi: 10.1080/09546634.2023.2285243. Epub 2023 Nov 20.

DOI:10.1080/09546634.2023.2285243
PMID:37985495
Abstract
摘要

相似文献

1
Assessment of patient-reported outcomes at 24 weeks of treatment with tralokinumab for atopic dermatitis: a multicentric real-life experience.特应性皮炎患者接受曲罗芦单抗治疗24周时的患者报告结局评估：一项多中心真实世界经验
J Dermatolog Treat. 2023 Dec;34(1):2285243. doi: 10.1080/09546634.2023.2285243. Epub 2023 Nov 20.
2
Health-related quality of life with tralokinumab in moderate-to-severe atopic dermatitis: A phase 2b randomized study.特利鲁单抗治疗中重度特应性皮炎的健康相关生活质量：一项 2b 期随机研究。
Ann Allergy Asthma Immunol. 2021 May;126(5):576-583.e4. doi: 10.1016/j.anai.2020.12.004. Epub 2020 Dec 15.
3
Tralokinumab improves clinical scores in adolescents with severe atopic dermatitis: A real-life multicentric observational study.曲罗芦单抗可改善重度特应性皮炎青少年的临床评分：一项真实世界多中心观察性研究。
J Eur Acad Dermatol Venereol. 2024 Mar;38(3):e288-e290. doi: 10.1111/jdv.19605. Epub 2023 Nov 10.
4
Tralokinumab treatment in atopic dermatitis: Depicting super-responders.特应性皮炎的曲罗芦单抗治疗：描绘超级应答者。
J Dermatol. 2023 Dec;50(12):1650-1652. doi: 10.1111/1346-8138.17009. Epub 2023 Oct 23.
5
Efficacy and safety of tralokinumab in the treatment of head and neck pattern atopic dermatitis: A multicentre study of 12 patients.特利鲁单抗治疗头颈部特应性皮炎模式的疗效和安全性：一项 12 例患者的多中心研究。
Australas J Dermatol. 2024 May;65(3):260-265. doi: 10.1111/ajd.14264. Epub 2024 Apr 8.
6
Tralokinumab Plus Topical Corticosteroids as Needed Provides Progressive and Sustained Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Over a 32-Week Period: An ECZTRA 3 Post Hoc Analysis.特利鲁单抗联合必要时的局部皮质类固醇在 32 周内为中重度特应性皮炎成人提供渐进和持续的疗效：ECZTRA 3 的事后分析。
Am J Clin Dermatol. 2022 Jul;23(4):547-559. doi: 10.1007/s40257-022-00702-2. Epub 2022 Jul 20.
7
Current treatment goals are achieved by the majority of patients with atopic dermatitis treated with tralokinumab: results from a multicentric, multinational, retrospective, cohort study.曲罗芦单抗治疗特应性皮炎患者的多数治疗目标达成：一项多中心、多国、回顾性队列研究结果。
Expert Opin Biol Ther. 2023 Jul-Dec;23(12):1307-1315. doi: 10.1080/14712598.2023.2292627. Epub 2023 Dec 28.
8
Tralokinumab rapidly improves subjective symptoms and quality of life in patients with moderate-to-severe atopic dermatitis: a real-life 16-week experience.曲罗芦单抗可迅速改善中度至重度特应性皮炎患者的主观症状和生活质量：一项为期16周的真实生活体验。
J Dermatolog Treat. 2023 Dec;34(1):2216815. doi: 10.1080/09546634.2023.2216815.
9
Real-Life Experience of Tralokinumab for the Treatment of Adult Patients with Severe Atopic Dermatitis: A Multicentric Prospective Study.特罗利单抗治疗成人重度特应性皮炎的真实世界临床经验：一项多中心前瞻性研究。
Clin Drug Investig. 2023 Apr;43(4):299-306. doi: 10.1007/s40261-023-01258-7. Epub 2023 Apr 3.
10
Tralokinumab in Atopic Dermatitis: A Profile of Its Use.特利鲁单抗治疗特应性皮炎：应用简介。
Clin Drug Investig. 2022 Apr;42(4):365-374. doi: 10.1007/s40261-022-01135-9. Epub 2022 Mar 22.

引用本文的文献

1
Effectiveness of Tralokinumab Across Atopic Dermatitis Phenotypes.度普利尤单抗在特应性皮炎各表型中的疗效。
J Clin Med. 2025 Mar 18;14(6):2077. doi: 10.3390/jcm14062077.
2
Single-centre experience with tralokinumab in dupilumab-experienced and naïve patients with atopic dermatitis.在使用度普利尤单抗的特应性皮炎患者和初治患者中使用曲罗芦单抗的单中心经验。
J Eur Acad Dermatol Venereol. 2025 Feb;39(2):e184-e186. doi: 10.1111/jdv.20348. Epub 2024 Sep 18.
3
Tralokinumab for the Treatment of Adult Atopic Dermatitis in Special Populations.
曲罗芦单抗用于特殊人群成人特应性皮炎的治疗
J Asthma Allergy. 2024 Aug 14;17:791-799. doi: 10.2147/JAA.S474411. eCollection 2024.
4
Type-2 immunity associated with type-1 related skin inflammatory diseases: friend or foe?与1型相关皮肤炎症性疾病相关的2型免疫：是友还是敌？
Front Immunol. 2024 May 29;15:1405215. doi: 10.3389/fimmu.2024.1405215. eCollection 2024.